Bengaluru-based medtech startup Bioscan Research has raised $1 million in a seed funding round led by Unicorn India Ventures to scale its non-invasive brain injury detection technology across new Indian markets. The fresh capital will help the company pursue additional regulatory approvals and upgrade its flagship diagnostic device.
Founded in 2017 by Anupam Lavania and Shilpa Malik, Bioscan Research builds affordable medical devices that combine optics, electronics, mechanics, software and machine learning to enable early detection of traumatic brain injuries. The company said the capital will be used to expand into new geographies, secure additional regulatory clearances, upgrade its flagship product, and develop new intellectual property around its optical-sensing approach.
Why Does Non-Invasive Brain Injury Detection Matter for India?
Traumatic brain injury is frequently under-diagnosed in India because conventional imaging such as CT and MRI scans is expensive, time-consuming and concentrated in urban hospitals. Bioscan Research’s non-invasive brain injury detection technology is designed to flag suspected injuries quickly at the point of care, particularly in trauma centres, ambulances and smaller hospitals that lack advanced imaging infrastructure. By combining optical sensors with machine learning algorithms, the device gives clinicians an early signal on whether a patient needs urgent imaging or specialist referral, a capability that could meaningfully cut diagnosis time in emergency settings.
What Does This Mean for India’s Medtech Startup Ecosystem?
Bioscan Research’s raise adds to a broader wave of medtech funding in India, where investors are increasingly backing affordable diagnostic hardware built for tier-2 and tier-3 markets rather than only premium urban hospitals. Because the device does not require the capital expenditure of an MRI or CT suite, hospitals and diagnostic chains can potentially adopt it at a fraction of the cost, widening access to brain injury screening across emergency rooms nationwide. Industry observers note that India’s medtech sector has struggled to compete with imported imaging equipment, making home-grown, IP-backed diagnostic hardware like Bioscan Research’s device notable for import substitution as well as affordability.
Industry Reaction and Expert Commentary
Unicorn India Ventures has backed the round as part of its continued focus on deep-tech and healthcare startups solving high-impact clinical problems with Indian-built hardware. The venture capital firm’s participation signals growing investor confidence in homegrown diagnostic technology that blends optics and machine learning, a category that has historically been dominated by imported imaging equipment in Indian hospitals. Healthcare-focused investors have pointed to affordable point-of-care diagnostics as one of the more resilient medtech sub-sectors for funding in 2026, even as overall startup funding remains selective.
What Happens Next?
Bioscan Research plans to use the fresh capital to pursue additional regulatory approvals that would allow wider clinical deployment, alongside a hardware upgrade to its flagship device. The company is also expected to expand its footprint beyond its existing markets and file new intellectual property covering its optical-sensing approach to brain injury diagnosis. Watch for pilot deployments in emergency departments and ambulance services as the next proof point for the technology.
Frequently Asked Questions
What does Bioscan Research’s device do?
It is a non-invasive diagnostic device that combines optics, electronics and machine learning to help detect traumatic brain injuries early, without requiring a CT or MRI scan.
Who led Bioscan Research’s $1 million funding round?
The seed round was led by Unicorn India Ventures, an early-stage venture capital firm that backs Indian deep-tech and healthcare startups.
Who founded Bioscan Research and when?
Bioscan Research was founded in 2017 by Anupam Lavania and Shilpa Malik to build affordable medical devices for early brain injury detection.
Leave a comment